Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models

KRAS is the most commonly mutated oncogene, yet no effective targeted therapies exist for KRAS mutant cancers. We developed a pooled shRNA-drug screen strategy to identify genes that, when inhibited, cooperate with MEK inhibitors to effectively treat KRAS mutant cancer cells. The anti-apoptotic BH3...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Corcoran, Ryan B., Cheng, Katherine A., Hata, Aaron N., Faber, Anthony C., Ebi, Hiromichi, Coffee, Erin M., Greninger, Patricia, Brown, Ronald D., Godfrey, Jason T., Cohoon, Travis J., Song, Youngchul, Lifshits, Eugene, Hung, Kenneth E., Shioda, Toshi, Dias-Santagata, Dora, Singh, Anurag, Settleman, Jeffrey, Benes, Cyril H., Mino-Kenudson, Mari, Wong, Kwok-Kin, Engelman, Jeffrey A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3667614/
https://ncbi.nlm.nih.gov/pubmed/23245996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2012.11.007
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg